Drug Discovery & DevelopmentOriginal article
Cocrystal Pharma’s single oral drug for multiple viruses
Phase 2CDI-988Positive
AI Analysis
Summary
Cocrystal Pharma is developing CDI-988, a pan-viral protease inhibitor targeting multiple viruses including norovirus and coronavirus. The lead candidate has completed Phase 2 development.
Clinical Trial Data
Phase
2
Importance:5/10
Sentiment:
0.30
pan-viral protease inhibitornoroviruscoronavirusclinical-stageoral treatment
Related Companies
Read the original article
Published by Drug Discovery & Development on August 10, 2026 6:20 PM